Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Phase 1/2 Clinical Study to Evaluate the Safety and Efficacy of BN301，An Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-cell Non-Hodgkin's Lymphoma

NCT05611853 is registered in ClinicalTrials.gov with BioNova Pharmaceuticals (Shanghai) LTD. as lead sponsor.

NCT NCT05611853
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05611853 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Phase 1/2 Clinical Study to Evaluate the Safety and Efficacy of BN301，An Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-cell Non-Hodgkin's Lymphoma
Lead sponsor
BioNova Pharmaceuticals (Shanghai) LTD.
Phase
Phase 1/2
Overall status
Terminated
Start date
November 25, 2022
Completion date
December 25, 2023
Enrollment
9 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell lymphoma, diffuse large b cell lymphoma, follicular lymphoma, mantle cell lymphoma, non hodgkin lymphoma